Longevity Market Misses $350B Opportunity in Underserved Perimenopausal and Menopausal Women
Event summary
- BCG's 2026 global study found $350B unmet demand in longevity market from 1B women in perimenopause/menopause
- Women in this life stage spend $84/month on longevity interventions, 15-22% higher adoption rates than other groups
- Only 63% of women consult doctors for hormone-related issues, with 72% feeling taken seriously vs. 85% for heart-related symptoms
- Women's interest in long-term health begins in mid-30s, a decade before market attention
- Report highlights persistent undiagnosed/undertreated health needs and lack of women's voice in longevity solutions
The big picture
The longevity market is leaving significant revenue on the table by overlooking the specific needs of women in perimenopause and menopause. This gap represents a strategic opportunity for companies that can develop targeted solutions, while also highlighting systemic issues in how women's health is addressed across the healthcare industry. The $350B unmet demand figure underscores both the market potential and the current failure to serve this critical demographic.
What we're watching
- Market Realignment
- How quickly longevity companies shift focus to earlier life stages for women
- Product Innovation
- Whether new solutions emerge to address the specific needs of perimenopausal/menopausal women
- Regulatory Dynamics
- The pace at which healthcare systems adapt to better serve women's hormone-related health needs